Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | PDE4A | P27815 | 6/20 | 0.60 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.60 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.60 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.60 |
| ▸ | ACHE | P22303 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4826029 | 0.98 | TSHR (0.72) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4826406 | 0.91 | PDE4A (0.76) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4825956 | 0.91 | PDE4A (0.64) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL5077500 | 0.91 | LMNA (0.63) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4824589 | 0.89 | PDE4A (0.64) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4822545 | 0.89 | PDE4A (0.62) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL20496433 | 0.89 | NPC1 (0.71) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1493250 | 0.87 | CYP1A2 (1.00) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4819890 | 0.87 | PDE4A (0.67) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4816909 | 0.87 | PDE4A (0.62) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1361210-B1 | Novel immunotherapeutic agents and their use in the reduction of cytokine levels | CELGENE CORP (US) | 2008-12-24 | — | — | EP | disclosed |
| US-7019030-B2 | Cyano and carboxy derivatives of substituted styrenes; inhibitors of tumor necrosis factor alpha, nuclear factor kappa B, and phosphodiesterase | CELGENE CORPORATION (US) | 2006-03-28 | — | — | US | disclosed |
| US-20040019106-A1 | Novel immunotherapeutic agents | MULLER GEORGE W (US) | 2004-01-29 | — | — | US | disclosed |
| EP-1361210-A2 | Novel immunotherapeutic agents and their use in the reduction of cytokine levels | CELGENE CORPORATION (US) | 2003-11-12 | — | — | EP | disclosed |
| US-20030045726-A1 | Novel immunotherapeutic agents | MULLER GEORGE W (US) | 2003-03-06 | — | — | US | disclosed |
| US-6479554-B2 | CYANO AND CARBOXY DERIVATIVES OF SUBSTITUTED STYRENES ARE INHIBITORS OF TUMOR NECROSIS FACTOR ALPHA , NUCLEAR FACTOR KAPPA B, AND PHOSPHODIESTERASE AND CAN BE USED TO TREAT CACHEXIA, ENDOTOXIC SHOCK, INFLAMMATORY CONDITIONS ETC. | CELGENE CORPORATION | 2002-11-12 | — | — | US | disclosed |
| US-20010056107-A1 | Novel immunotherapeutic agents | MULLER GEORGE W (US) | 2001-12-27 | — | — | US | disclosed |
| US-6262101-B1 | ALPHA-PYRROLIDINE, IMIDAZOLE AND THIOPHENE-SUBSTITUTED STYRENE DERIVATIVES; INHIBITORS OF TUMOR NECROSIS FACTOR ALPHA, NUCLEAR FACTOR KAPPA B, AND PHOSPHODIESTERASE | CELGENE CORPORATION | 2001-07-17 | — | — | US | disclosed |
| US-6130226-A | Immunotherapeutic agents | CELGENE CORPORATION (US) | 2000-10-10 | — | — | US | disclosed |
| US-5929117-A | COMPOUNDS WHICH MEDIATE ACTION OF PHOSPHODIESTERASE AND FORMATION OF TUMOR NECROSIS FACTOR AND NUCLEAR FACTORS | CELGENE CORPORATION (US) | 1999-07-27 | — | — | US | disclosed |
| EP-0918746-A1 | IMMUNOTHERAPEUTIC AGENTS AND THEIR USE IN THE REDUCTION OF CYTOKINE LEVELS | CELGENE CORPORATION (US) | 1999-06-02 | — | — | EP | disclosed |
| WO-1998006692-A1 | NOVEL IMMUNOTHERAPEUTIC AGENTS AND THEIR USE IN THE REDUCTION OF CYTOKINE LEVELS | CELGENE CORPORATION (US) | 1998-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045726-A1 | Novel immunotherapeutic agents | NFKBIA, RELA, IKBKG | TSHR 4432/4885CYP1A2 3471/4885CYP3A4 3495/4885 |
| US-20040019106-A1 | Novel immunotherapeutic agents | NFKBIA, RELA, IKBKG | TSHR 4432/4885CYP1A2 3471/4885CYP3A4 3495/4885 |
| US-20010056107-A1 | Novel immunotherapeutic agents | NFKBIA, RELA, IKBKG | TSHR 4432/4885CYP1A2 3471/4885CYP3A4 3495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.